Overall survival at 5 years of follow-up in a phase III trial comparing ipilimumab 10 mg/kg with 3 mg/kg in patients with advanced melanoma

by Gabriella Liszkay, Catriona McNeil, Michele Maio, Vanna Chiarion-Sileni, Luc Thomas, Andrzej Mackiewicz, Michelle Del Vecchio, Ana Arance, Laurent Mortier, Lars Bastholt, Brigitte Dreno, Marta Nyakas, Michael Smylie, Christoph Hoeller, Virginia Ferraresi, Florent Grange, Joanna Pikiel, Fareeda Hosein, Burcin Simsek
Published 2020-06-01